Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 2Meningeal Carcinomatosis 1Glioma 1

Interventions

Specimen Handling 449Magnetic Resonance Spectroscopy 344pembrolizumab 296Biopsy 247Carboplatin 235Cisplatin 198Cyclophosphamide 190Paclitaxel 167Nivolumab 158Gemcitabine 154Bevacizumab 125Radiotherapy 122Dexamethasone 115fludarabine 102Pemetrexed 102Fluorouracil 96Doxorubicin 92venetoclax 91durvalumab 91Radiation 91Docetaxel 91atezolizumab 90Oxaliplatin 89Rituximab 88Leucovorin 82Capecitabine 78Prednisone 77Lenalidomide 71Etoposide 69X-Rays 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × azeliragon × 30 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡